ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

ARDX Ardelyx Inc

6.59
0.04 (0.61%)
Apr 18 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 3,735,253
Bid Price 6.45
Ask Price 6.61
News (1)
Day High 6.565

Low
3.16

52 Week Range

High
10.13

Day Low 6.39
Company Name Stock Ticker Symbol Market Type
Ardelyx Inc ARDX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.04 0.61% 6.59 19:51:10
Open Price Low Price High Price Close Price Prev Close
6.53 6.39 6.565 6.44 6.55
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
20,069 3,735,253 $ 6.48 $ 24,222,547 - 3.16 - 10.13
Last Trade Time Type Quantity Stock Price Currency
19:55:54 12 $ 6.46 USD

Ardelyx (ARDX) Options Flow Summary

Overall Flow

Bullish

Net Premium

38k

Calls / Puts

100.00%

Buys / Sells

0.00%

OTM / ITM

0.00%

Sweeps Ratio

0.00%

Ardelyx Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
1.5B 232.69M - 124.46M -66.07M -0.28 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Ardelyx News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ARDX Message Board. Create One! See More Posts on ARDX Message Board See More Message Board Posts

Historical ARDX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week7.177.436.396.934,650,209-0.58-8.09%
1 Month7.868.026.397.295,181,925-1.27-16.16%
3 Months8.5610.136.398.415,608,716-1.97-23.01%
6 Months3.9110.133.406.756,422,8172.6868.54%
1 Year5.0410.133.165.485,854,0861.5530.75%
3 Years8.8010.130.49023.026,793,340-2.21-25.11%
5 Years3.4310.43430.49023.274,371,2473.1692.13%

Ardelyx Description

Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of molecule and polymeric therapeutics to treat the gastrointestinal tract and cardiorenal diseases. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.

Your Recent History

Delayed Upgrade Clock